Beam Therapeutics Inc. Common Stock (BEAM)

Price$31.14

Value ScoreD

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)43.92%

Price vs S&P 500 (4W)2.29%

VGM Score70.06

Market Capitalization$3.39B

All Metrics

Book Value / Share (Quarterly)$11.33

P/TBV (Annual)3.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)31.88%

Cash Flow / Share (Quarterly)$-3.74

Price vs S&P 500 (YTD)7.86%

Net Profit Margin (TTM)-39.66%

EPS (TTM)$-0.64

10-Day Avg Trading Volume1.87M

EPS Excl Extra (TTM)$-0.64

Revenue Growth (5Y)487.30%

EPS (Annual)$-0.81

ROI (Annual)-6.46%

Net Profit Margin (5Y Avg)-374.99%

Cash / Share (Quarterly)$11.79

Revenue Growth QoQ (YoY)324.87%

ROA (Last FY)-5.40%

Revenue Growth TTM (YoY)157.97%

EBITD / Share (TTM)$-3.40

ROE (5Y Avg)-31.11%

Operating Margin (TTM)-226.58%

Cash Flow / Share (Annual)$-3.54

P/B Ratio2.91x

P/B Ratio (Quarterly)2.08x

Net Income / Employee (Annual)$-156,500

EV / Revenue (TTM)19.51x

Net Interest Coverage (TTM)-365.97x

ROA (TTM)-4.59%

EPS Incl Extra (Annual)$-0.81

Current Ratio (Annual)13.09x

Quick Ratio (Quarterly)16.25x

3-Month Avg Trading Volume2.00M

52-Week Price Return101.78%

Revenue / Employee (TTM)$321,000

Tangible BV / Share (Quarterly)$9.81

P/S Ratio (Annual)24.24x

Asset Turnover (Annual)0.09x

52-Week High$36.44

Operating Margin (5Y Avg)-457.65%

EPS Excl Extra (Annual)$-0.81

CapEx CAGR (5Y)-1.79%

26-Week Price Return59.85%

Quick Ratio (Annual)12.85x

13-Week Price Return13.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)16.99x

Enterprise Value$3.20B

Revenue / Share Growth (5Y)412.40%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)23.21%

Revenue / Employee (Annual)$273,500

Pretax Margin (Annual)-57.24%

Cash / Share (Annual)$12.24

3-Month Return Std Dev66.46%

Net Income / Employee (TTM)$-127,300

ROE (Last FY)-6.46%

Net Interest Coverage (Annual)-9.73x

EPS Basic Excl Extra (Annual)$-0.81

Receivables Turnover (TTM)0.41x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$-0.64

Receivables Turnover (Annual)0.41x

ROI (TTM)-5.76%

P/S Ratio (TTM)20.66x

Pretax Margin (5Y Avg)-365.42%

Revenue / Share (Annual)$1.41

Tangible BV / Share (Annual)$10.29

Price vs S&P 500 (52W)73.57%

Year-to-Date Return18.80%

5-Day Price Return14.98%

EPS Normalized (Annual)$-0.81

ROA (5Y Avg)-19.06%

Net Profit Margin (Annual)-57.24%

Month-to-Date Return8.57%

Cash Flow / Share (TTM)$-3.96

EBITD / Share (Annual)$-3.65

Operating Margin (Annual)-274.57%

LT Debt / Equity (Annual)0.16x

ROI (5Y Avg)-31.02%

LT Debt / Equity (Quarterly)0.09x

EPS Basic Excl Extra (TTM)$-0.64

P/TBV (Quarterly)3.10x

P/B Ratio (Annual)2.27x

Pretax Margin (TTM)-39.66%

Book Value / Share (Annual)$12.17

Price vs S&P 500 (13W)4.12%

Beta2.21x

Revenue / Share (TTM)$1.59

ROE (TTM)-5.89%

52-Week Low$15.35

vGradeD

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.91est. -1.12

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.33

4.32

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
BEAMBeam Therapeutics Inc. Common Stock	D	A	B	$31.14
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Beam Therapeutics is a precision genetic medicine company leveraging proprietary base editing technology to develop lifelong cures for serious diseases. The company's pipeline focuses on hematologic and genetic disorders, with lead programs including BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency. Operations are based in the United States.